About: Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $99.55 (+4.32%)
ORKA NASDAQ Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. share price
ORKA price activity
Last Price
$99.550
Change (24hr)
4.12 USD (4.32%)
Volume
822
Volume (4w avg)
-
Previous Close
$95.43
Last Trade
04 Nov, 2:18 pm GMT+0
Delayed
04 Nov, 2:18 pm GMT+0
ORKA price performance
Delayed
04 Nov, 2:18 pm GMT+0
ORKA details
ORKA Market Signals